Key result
Trimetazidine improves cardiac function and exercise capacity in HF by inhibiting free fatty acid oxidation.
Answers are grounded in this paper and cite their sources.
Modulating cardiac metabolism by partially inhibiting free fatty acid oxidation, primarily with trimetazidine, is a beneficial complementary approach in heart failure management.
Heart failure is associated with altered cardiac metabolism, in part, due to maladaptive mechanisms, in part secondary to comorbidities such as diabetes and ischemic heart disease. The metabolic derangements taking place in heart failure are not limited to the cardiac myocytes but extend to skeletal muscles and the vasculature causing changes that contribute to the worsening of exercise capacity. Modulation of cardiac metabolism with partial inhibition of free fatty acid oxidation has been shown to be beneficial in patients with heart failure. At the present, the bulk of evidence for this class of drugs comes from trimetazidine. Newer compounds partially inhibiting free fatty acid oxidation or facilitating the electron transport on the mitochondrial cristae are in early phase of their clinical development.
No takes yet. Share an insight, caveat, or question.
Rosano et al. (2024) conducted a review in Heart failure. Metabolic modulators (e.g., trimetazidine) was evaluated. Modulation of cardiac metabolism with partial inhibition of free fatty acid oxidation, primarily with trimetazidine, improves cardiac function and exercise capacity in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: